B-cell chronic lymphocytic leukemia (B-CLL) is characterized by a highly variable clinical course. At present, mutation status of the immunoglobulin heavy-chain variable region (IgVH) represents the most significant prognostic marker, with patients manifesting a high germline homology (X98%) having a significantly worse prognosis. 1, 2 The unmutated IgVH locus is associated with the presence of unfavorable genomic aberrations: the 11q deletion (likely to involve the ATM kinase) is associated very strongly, 1,2 whereas the association for the 17p deletion (involving the p53 gene) varies in different studies from strong 1 to that of borderline statistical significance. 2 Abnormalities in these two loci seem to be mutually exclusive in B-CLL cells 3 and they markedly deteriorate an already bad prognosis for IgVH-unmutated patients. 1, 2 Two recent studies 4,5 also saw a strong association between the occurrence of p53 inactivation in B-CLL patients and the presence of previous treatment, indicating a possible involvement of DNA-damaging chemotherapy in the process of selection or even induction of p53 mutations. These two studies did not, however, analyze the IgVH mutation status. It is well known that a much higher proportion of B-CLL patients bearing the germline IgVH sequence require treatment compared to IgVH-mutated patients. We therefore decided to correlate p53 inactivation with both the IgVH mutation status and the presence of previous therapy in a large cohort of B-CLL patients. The patient population was also studied for the presence of ATM locus deletions.
In order to achieve the maximal efficiency for p53 mutation screening, we used a very sensitive functional yeast assay (FASAY). 6 The samples were also screened by Western blotting (WB) in order to search for an abnormal p53 protein level, which is known often to be underlined by a gene mutation in tumor cells. The data concerning p53 and ATM deletions were obtained using interphase fluorescent in situ hybridization (I-FISH) with locus-specific probes. PCR and direct sequencing were used to analyze the IgVH rearrangements and mutation status. A summary of basic data regarding the patients evaluated is provided in Table 1 and a summary of the tests performed is listed in Table 2 .
The blood and bone marrow samples were obtained with written informed consent and total RNA or proteins were isolated from mononuclear cells separated on histopaque gradient. As the FASAY is able to identify a mutation within a large fraction of cells bearing normal p53, it is especially suitable for B-CLL, where the p53-mutated cells often represent a clonal variant of the leukemic population. In this assay, the central part of the p53 gene (amplified from cDNA between exons 4 and 10, i.e. codons 42-374) is introduced into an ADE2
À yeast strain carrying a reporter with a p53-binding site upstream of the ADE2 gene. On the plates containing a low level of adenine, the p53 wild-type (wt-p53) samples then form large white colonies, whereas the colonies with the p53 mutations (mut-p53) are small and red, owing to limited growth and accumulation of a reddish product of adenine metabolism. Samples containing a wt-p53 gene account for more than 90% of white colonies in the assay, whereas the remaining 10% represent background -a consequence of PCR-induced point mutations or a low-quality RNA. 6 We showed previously 7 that FASAY provides the expected numbers of red colonies when using serial dilutions of wt-p53 and mut-p53 plasmids for PCR amplification or when using leukemic cell lines with known p53 status. We also observed that in properly handled clinical samples (which allow a standard PCR amplification), the background of FASAY is usually under 10%.
We performed the FASAY on 168 leukocyte samples derived from peripheral blood. Twenty-three cases (13.7%) provided an elevated portion of red colonies. In 10 samples, the Split assay, a modified version of FASAY analysis, which tests the 5 0 and 3 0 halves of the gene separately, was performed. This approach was used when the number of red colonies did not get over 20% and the PCR product used for transformation was normal, or did not get over 40% and the PCR product was too faint. Using this method, we confirmed the mutation identified by FASAY in six samples, whereas the remaining four samples bore the wt-p53. The other four samples, identified by FASAY as mutated ones, were later shown to harbor an alternative splicing (discussed later). Thus, in summary, 15 samples (9%) were confirmed as mutated after we completed the FASAY, Split assay and sequencing. The results of sequencing are provided in Table 3 . A relationship between occurrence of p53 or ATM abnormalities and mutation status of IgVH was evaluated using relative risk (RR) with 95% CIs (confidence intervals) and odds ratios (ORs) with 95% CIs. The P-values (significance level) were calculated using the w 2 test for association. a ts -The temperature-sensitive p53 mutants.
In all 15 p53-mutated samples, a corresponding base change was identified unambiguously. Surprisingly, none of the mutations were detected more than once and we therefore do not see the mutation hotspots emerging for the B-CLL in the p53 mutation database (codons 175, 248 and 273; wwwp53.iarc.fr). The reason for these population differences in the frequency of p53 mutations remains elusive, especially because we know little about functional consequences of different mutations (i.e. there may be different mutations reported in individual studies but leading to the same defective phenotype).
To our knowledge, we report for the first time in B-CLL an alternatively spliced variant of the p53 transcript, which we identified in four patients. The transcript includes a 133-bp insertion of intron 9 sequence, which results in a truncated protein of 341 amino acids. This alternative transcript was shown to be expressed in normal human cells, especially quiescent peripheral blood lymphocytes, where it was 'hidden' within 10% of background red colonies in FASAY. 8 The protein exhibits a defective tetramerization domain with the consequence of a transcriptional defect in mammalian cells in vivo. We detected this version of the p53 in four patients, giving 30, 30, 24 and 14% of red colonies, respectively. All of them were without a mutation in the p53 gene, did not express a detectable level of protein on WB, were without cytogenetic defects in p53 or ATM locuses, were not previously treated and all manifested mutated-IgVH genotype with supposed indolent course. The last correlation in particular is interesting. If proven in a larger number of patients, it could be another indicator of more quiescent state of the IgVH-mutated B-CLL cells. As Flaman et al. 8 identified this transcript in healthy human cells, we excluded this version of p53 abnormality from the set of mutations, or p53-inactivated samples, in our report.
In order to verify the mutations identified by FASAY and reveal other potential p53 abnormalities, not underlined by a mutation in the gene, we monitored the p53 protein level. We found a very good correlation between the high p53 protein level (detected by WB with DO-1 Mab) and a corresponding mutation (12/13, 92%; see also Table 3 ; figure of the WB's is not shown). There was also a good overlap between the deletion and accompanying mutation in the p53 locus; however, this was not absolute (72%; see Table 3 ). In spite of using a complex approach and extremely sensitive FASAY methodology, the overall percentage of p53 inactivation (12%) is within the expected range. An interesting phenomenon is the remarkable difference in the percentage of red (p53-mutated) colonies and percentage of p53-deleted cells detected by I-FISH. As both tests provide at least a semiquantitative (i.e. not absolutely exact but, also, not to a substantial extent misleading) estimate of the percentage of defected cells, these differences might theoretically reflect the order of acquirement of p53 mutation and deletion, respectively. These conclusions, however, require caution, and consecutive tests performed on samples derived during the course of the disease will be necessary to further clarify the response to this question.
The heterozygous ATM locus deletion was present in 21 samples (18%; extent 20-93% of the cells) and there was the only patient with the parallel abnormality in the p53 locus (case D2 in Table 3 ). We therefore confirm, in a large cohort of patients, the previous finding 3 that the ATM abnormalities are highly likely an alternative to the p53 dysfunction (Po0.001 in our set of patients). The results also confirm 2 a very strong association between the presence of ATM deletion and the presence of the germline IgVH sequence (20/69 ¼ 29% vs 0/35 ¼ 0% in IgVH-mutated subgroup; Po0.001). We did not, , parallel deletion of ATM locus in 56% of the cells. The cutoff level for the detection of p53-and ATM-deleted cells by I-FISH (5% for both probes) was calculated in a series of 15 samples obtained from normal bone marrow donors (200 interphase nuclei per slide were evaluated) using the upper limit of binomial confidence interval. Sequences deviating more than 2% from the nearest germ line were considered to be IgVH-mutated. The closest germline VH was assigned using DNA plot or IgBlast databases. The mutations M3, M7, M13 and M14 were temperature-sensitive.
Letters to the Editor however, monitor the status of the second allele and it is hence not clear what proportion of deleted samples were really ATMinactivated. The p53 abnormalities were also detected markedly more frequently in the unmutated-IgVH subtype compared to the mutated one (15/90 ¼ 16.7% vs 3/57 ¼ 5.3%; Po0.05). Moreover, two of the three IgVH-mutated cases harbored just a single p53 deletion without an accompanying mutation.
The p53 abnormalities occurred more frequently in previously treated patients than in untreated ones (18.4 vs 9.2%) and a similar trend is also seen for the ATM deletion (18 vs 10%). There was an obvious difference in the proportion of treated patients between the IgVH-mutated and IgVH-unmutated subgroups. In the former, only 7% of patients were previously treated -none of them with the p53 abnormality or ATM deletion. By contrast, within the latter subgroup, 49% of patients were previously treated and the percentage with the p53 abnormality in both treated and untreated patients was similar (20 vs 17%), which was also the case for ATM deletion (20 vs 26%). The p53 inactivation therefore occurred in a proportion of patients who had not received any previous therapy, and in these cases the abnormalities likely originate from spontaneous mutagenesis. The possibility, however, that DNA-damaging chemotherapy may induce or select p53 mutations in the other, previously treated, B-CLL cases cannot be rejected. This serious question warrants further detailed investigation, in particular a consecutive follow-up of the inactivation before and after treatment. Already, after a short follow-up, our study could also confirm an inferior prognosis for the patients having a p53 abnormality, as evidenced by an almost inevitable requirement for treatment and short survival time for many patients (see Table 4 ).
In addition, and in conclusion, we emphasize that FASAY may add a new quality to p53 mutation screening in B-CLL patients and may appropriately supplement a routine cytogenetic screening.
